Flag of the European Union EU Clinical Trials Register Help

Clinical trials for infliximab (remicade)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    155 result(s) found for: infliximab (remicade). Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2014-004904-31 Sponsor Protocol Number: IFX4501 Start Date*: 2015-05-19
    Sponsor Name:Mundipharma Pharmaceuticals B.V.
    Full Title: An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s ...
    Medical condition: Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007519-34 Sponsor Protocol Number: FAST VERSION Start Date*: 2009-04-17
    Sponsor Name:University of Leuven Hospitals, Division of Gastroenterology
    Full Title: Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST
    Medical condition: This is a open label, prospective, multicenter trial in patients recieving one hour infusions of infliximab (i.e. Remicade)as part of their daily practice. Main objective: Is to assess the tolerab...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004969-14 Sponsor Protocol Number: 2111 Start Date*: 2014-01-28
    Sponsor Name:Heidi Mäkinen
    Full Title: Measurement of levels of infliximab and anti-infliximab antibodies in rheumatic patients
    Medical condition: rheumatic diseases
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10072736 Rheumatic disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000570-28 Sponsor Protocol Number: IFX001PSHP Start Date*: 2021-11-09
    Sponsor Name:Tampere University Hospital
    Full Title: Accelerated infliximab infusions in inflammatory bowel disease, Phase IV trial
    Medical condition: Inflammatory bowel diseases
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013869-26 Sponsor Protocol Number: P06119 Start Date*: 2009-10-02
    Sponsor Name:Associação para Desenvolvimento da Dermatologia do Hospital de Santa Maria
    Full Title: "Influence of Remicade (infliximab) in the skin proteome of psoriatic patients"
    Medical condition: This pilot lab-based study will assess skin biopsies from psoriatic patients treated with infliximab and aim to compare the proteomic profiles of samples obtained under the following conditions: 1-...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037153 Psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001064-11 Sponsor Protocol Number: NI071F2 Start Date*: 2017-07-18
    Sponsor Name:Nichi-Iko Pharmaceutical Co., Ltd.
    Full Title: A Randomized, Double-Blind, Multicenter, 3-Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005629-21 Sponsor Protocol Number: Tech-infliximab2014/1 Start Date*: 2014-08-14
    Sponsor Name:First Department of Medicine, University of Szeged
    Full Title: Diagnostic use of 99mTecnetium labeled infliximab in Crohn’s disease
    Medical condition: Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001131-35 Sponsor Protocol Number: 08-0106-stop Start Date*: 2008-05-14
    Sponsor Name:Academic Medical Center, department of Gastroenterology and hepatology
    Full Title: Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial
    Medical condition: this study is designed as a multicenter radomized trial comparing azathioprine maintenance treatment to infliximab maintenance treatment in Crohn's disease patients that are in remission for at lea...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002224-26 Sponsor Protocol Number: INFLIXIMABDOSE01 Start Date*: 2015-05-07
    Sponsor Name:St. Antonius Hospital
    Full Title: A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment
    Medical condition: Sarcoidosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001853-17 Sponsor Protocol Number: AGO/2008/003 Start Date*: 2008-06-26
    Sponsor Name:University Hospital Ghent
    Full Title: Invloed van behandeling met infliximab op immuuncellen in het bloed van patiënten met spondyloartritis
    Medical condition: spondyloartritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058338 Spondylarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002460-29 Sponsor Protocol Number: EASIC30505 Start Date*: 2005-09-12
    Sponsor Name:Rheumazentrum Ruhrgebiet.
    Full Title: An Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC...
    Medical condition: Ankylosing spondylitis (AS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001633-14 Sponsor Protocol Number: HUM 05-001 Start Date*: 2005-08-17
    Sponsor Name:Hvidovre Hospital, Dept. Rheumatology
    Full Title: Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira) 40 mg s.c. eow versus infliximab (Remicade) 3 mg/kg i.v. every 6. week in RA patients with unsustainable c...
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004463-25 Sponsor Protocol Number: RHMMED1716 Start Date*: 2020-12-15
    Sponsor Name:University Hospital Southampton NHS Trust
    Full Title: SWitching InflixiMab to SUbcut from Intravenous Therapy
    Medical condition: Crohn's Disease Ulcerative Colitis Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-004694-26 Sponsor Protocol Number: P1200/001 Start Date*: 2007-09-17
    Sponsor Name:Saint-Luc Universitary Hospital
    Full Title: A Comparative Study Of A 6-Month Infliximab (Remicade) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis : Clinical, Radiological (MRI) And S...
    Medical condition: Patient with undifferentiated arthritis and the presence of anti-CCP antibodies are at high risk to develop RA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004497-10 Sponsor Protocol Number: CT-P13-3.4 Start Date*: 2014-07-16
    Sponsor Name:Celltrion, Inc.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease
    Medical condition: Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10058815 Crohn's disease acute episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) RO (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004067-30 Sponsor Protocol Number: CO168X94 (EU-116) Start Date*: 2006-05-08
    Sponsor Name:Department of Rheumatology, Internal Medicine III, Medical University of Vienna
    Full Title: A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Ery...
    Medical condition: Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004618-10 Sponsor Protocol Number: PACIFIC Start Date*: 2016-04-19
    Sponsor Name:CUB- Hopital Erasme
    Full Title: Study of the inter-individual variation of PhArmaCo-kinetics of InFliximab during treatment Induction in patients with Crohn’s disease and Ulcerative Colitis
    Medical condition: Patients with Crohn disease or Ulcerative Colitis which need biotherapy (antibody against TNF-a)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001113-33 Sponsor Protocol Number: AGO/REU/04/01 Start Date*: 2004-10-13
    Sponsor Name:University Hospital Ghent
    Full Title: Effect of TNFalpha blockade on the induction of specific B cell responses in vivo, using human spondyloarthropathy as model.
    Medical condition: Spondyloarthropathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000815-15 Sponsor Protocol Number: BOS-1168-WEI-0080-I Start Date*: 2011-08-02
    Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen
    Full Title: BOSTRIP (Investigator Initiated Trial) (Biomarkers of systemic treatment response in Psoriasis) Differential analysis of metabolomic profiles in patients with chronic plaque psoriasis underg...
    Medical condition: Psoriasis is a chronic hyperproliferative and inflammatory skin disease with its major subtype, chronic plaque-type psoriasis, affecting approximately 2% of individuals in Western populations. It m...
    Disease:
    Population Age: Elderly Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004074-10 Sponsor Protocol Number: 932 Start Date*: 2007-11-27
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: “Idiopathic sudden sensorineural hearing loss treatment by Infliximab injection (TNF-alfa blocker)”
    Medical condition: idiopathic sudden hearing loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027666 Ear disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 08:38:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA